Jun, Gyungah R.You, YangZhu, CongcongMeng, GaoyuanChung, JaeyoonPanitch, RebeccaHu, JunmingXia, WeimingThe Alzheimer’s Disease Genetics ConsortiumBennett, David A.Foroud, Tatiana M.Wang, Li-SanHaines, Jonathan L.Mayeux, RichardPericak-Vance, Margaret A.Schellenberg, Gerard D.Au, RhodaLunetta, Kathryn L.Ikezu, TsuneyaStein, Thor D.Farrer, Lindsay A.2024-05-012024-05-012022Jun GR, You Y, Zhu C, et al. Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE ɛ2 for Alzheimer's disease. Alzheimers Dement. 2022;18(11):2042-2054. doi:10.1002/alz.12607https://hdl.handle.net/1805/40401Introduction: The apolipoprotein E (APOE) ɛ2 allele reduces risk against Alzheimer's disease (AD) but mechanisms underlying this effect are largely unknown. Methods: We conducted a genome-wide association study for AD among 2096 ɛ2 carriers. The potential role of the top-ranked gene and complement 4 (C4) proteins, which were previously linked to AD in ɛ2 carriers, was investigated using human isogenic APOE allele-specific induced pluripotent stem cell (iPSC)-derived neurons and astrocytes and in 224 neuropathologically examined human brains. Results: PPP2CB rs117296832 was the second most significantly associated single nucleotide polymorphism among ɛ2 carriers (P = 1.1 × 10-7 ) and the AD risk allele increased PPP2CB expression in blood (P = 6.6 × 10-27 ). PPP2CB expression was correlated with phosphorylated tau231/total tau ratio (P = .01) and expression of C4 protein subunits C4A/B (P = 2.0 × 10-4 ) in the iPSCs. PPP2CB (subunit of protein phosphatase 2A) and C4b protein levels were correlated in brain (P = 3.3 × 10-7 ). Discussion: PP2A may be linked to classical complement activation leading to AD-related tau pathology.en-USAttribution-NonCommercial-NoDerivatives 4.0 InternationalAlzheimer's diseaseApolipoprotein EC4BHuman induced pluripotent stem cellsPPP2CBTau proteinProtein phosphatase 2A and complement component 4 are linked to the protective effect of APOE ɛ2 for Alzheimer's diseaseArticle